More vaccine shots….
The seven day infection case average is slightly below what it was last August….
Governor’s opening up their states more….
More pandemic money on the way to states from Biden/Congress Stimulus/Rescue Bill passage…
And a possible 4th vaccine could be approved in the near future…
In the past week in the U.S….
Among reported tests, the positivity rate was 4.3%.
The number of tests reported fell 7.7% from the previous week.Read more
Since Dec. 14, more than 98,203,000 doses of a covid-19 vaccine have been administered in the U.S.
More than 33,863,000 people have completed vaccination, or about 10.2% of the population. Read more in our vaccination tracker.
Wash Post …Link
The State of the Virus
Update for March 9
- March began with some of the lowest case numbers the country had seen since last fall, though the pace of progress has slowed.
- While many states have continued to see significant declines in new cases, others, especially on the East Coast, have seen infections plateau at relatively high levels.
- Daily death reports have fallen steadily from their peak earlier this year. But thousands of people continue to die from the virus each week.
- The pace of vaccination has increased steadily in recent weeks, to more than 2 million doses on average each day. With three vaccines now in circulation, many states are expanding eligibility for the shots.
- The source of our hospitalizations and testing data was changed to the U.S. Department of Health and Human Services after the Covid Tracking Project stopped collecting data on March 7.
A possible 4th vaccine….96% effective….
The COVID-19 vaccine from Novavax was found to be 96 percent effective against the original strain of the coronavirus in new a UK trial, the company announced Thursday.
The shot from the Maryland-based company was also 86 percent effective against the more contagious variant first discovered in the UK and now spreading across the US and in New York City.
In a smaller South Africa trial, the Novavax vaccine was only around 55 percent effective in preventing disease when tested against volunteers primarily exposed to the new variant first identified there.
But in both the UK and South Africa trials, the shot was 100 percent effective in preventing serious illness and death.
The company will use the findings to seek authorization for the vaccine’s use in various countries. It was not immediately clear if it will seek FDA authorization based on the UK findings, or if it will wait for the completion of an ongoing US test….